A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). M...
Saved in:
| Published in | Breast cancer research and treatment Vol. 140; no. 2; pp. 331 - 339 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Boston
Springer US
01.07.2013
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/m
2
. Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/m
2
. Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease ≥6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. |
|---|---|
| AbstractList | Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/[m.sup.2]. Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/[m.sup.2]. Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease [greater than or equal to] 6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. Keywords Metastatic breast cancer * Paclitaxel * Tivozanib * VEGFR inhibitor Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/m 2 . Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/m 2 . Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease ≥6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/m(2). Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/m(2). Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease ≥6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/m(2). Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/m(2). Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease ≥6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/[m.sup.2]. Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/[m.sup.2]. Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease [greater than or equal to] 6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/m^sup 2^. Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/m^sup 2^. Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease >=6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging.[PUBLICATION ABSTRACT] |
| Audience | Academic |
| Author | Beckman, J. Duarte, A. Steelman, L. Strahs, A. L. Winer, E. P. Agarwal, S. Mayer, Erica L. Scheulen, M. E. Dickler, M. N. Richly, H. Cotreau, M. M. |
| Author_xml | – sequence: 1 givenname: Erica L. surname: Mayer fullname: Mayer, Erica L. email: emayer@partners.org organization: Dana-Farber Cancer Institute – sequence: 2 givenname: M. E. surname: Scheulen fullname: Scheulen, M. E. organization: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen – sequence: 3 givenname: J. surname: Beckman fullname: Beckman, J. organization: Brigham and Women’s Hospital – sequence: 4 givenname: H. surname: Richly fullname: Richly, H. organization: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen – sequence: 5 givenname: A. surname: Duarte fullname: Duarte, A. organization: AVEO Oncology – sequence: 6 givenname: M. M. surname: Cotreau fullname: Cotreau, M. M. organization: AVEO Oncology – sequence: 7 givenname: A. L. surname: Strahs fullname: Strahs, A. L. organization: AVEO Oncology – sequence: 8 givenname: S. surname: Agarwal fullname: Agarwal, S. organization: AVEO Oncology – sequence: 9 givenname: L. surname: Steelman fullname: Steelman, L. organization: AVEO Oncology – sequence: 10 givenname: E. P. surname: Winer fullname: Winer, E. P. organization: Dana-Farber Cancer Institute – sequence: 11 givenname: M. N. surname: Dickler fullname: Dickler, M. N. organization: Memorial Sloan-Kettering Cancer Center |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27632562$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23868188$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kl9vFCEUxSemxm6rH8AXQ2La-DIVmD_A46Zpa5MmGqO-Eoa5dKjssAJj3b75zWWyq22NhgcI_M65wD0Hxd7oRyiKlwSfEIzZ20hwU4sSk6qkbUVL8aRYkIZVJaOE7RULTFpWthy3-8VBjDcYY8GweFbs04q3nHC-KH4u0YdBRUCXqPcRSohaOZWsH1FMU79B3qA0APpydnH-EdlxsJ1NPqBkv_s7NdoODZs-eD04H2wP6NamAd0CfHUbtFba2aR-gMtCtIKkYsrWGnUB8hJpNWoIz4unRrkIL3bzYfH5_OzT6bvy6v3F5enyqtQNxqkUPTeE8p5AS_uOCdEZ1lHKOiUIE8qoxjSqYS3TWnAOdcd1S3UjeMsMU6apDos3W9918N8miEmubNTgnBrBT1GSmnBSV03DM_r6L_TGT2HMt5spVmNKMbunrpUDaUfjU1B6NpXLqq5bXFE8lz35B5VHDyurcz-NzfuPBMcPBAMol4bo3TT3JD4GyRbUwccYwMh1sCsVNpJgOedDbvMhcz7knA8psubV7mVTt4L-j-J3IDJwtAPUnAQTco9svOdY9mlamjm65WI-Gq8hPPii_1b_BXI10mw |
| CODEN | BCTRD6 |
| CitedBy_id | crossref_primary_10_1016_j_pharmthera_2014_11_004 crossref_primary_10_2174_1568026622666220308161710 crossref_primary_10_1007_s40262_015_0302_2 crossref_primary_10_1093_annonc_mdw444 crossref_primary_10_2217_fon_13_253 crossref_primary_10_1158_1078_0432_CCR_15_3117 crossref_primary_10_1002_cpdd_145 crossref_primary_10_1016_j_ctrv_2020_101966 crossref_primary_10_3390_ijms23126806 crossref_primary_10_1016_j_ygyno_2021_08_005 crossref_primary_10_1177_1758835920923818 crossref_primary_10_1517_13543784_2014_895323 crossref_primary_10_1038_s41598_018_22302_z crossref_primary_10_3390_ijms150813768 crossref_primary_10_1177_1010428317711033 crossref_primary_10_1007_s11912_015_0451_3 crossref_primary_10_1007_s11060_016_2332_5 crossref_primary_10_1517_13543784_2015_1005736 crossref_primary_10_1016_j_jash_2018_03_008 |
| Cites_doi | 10.1158/0008-5472.CAN-03-2970 10.1200/JCO.2011.36.4133 10.1158/1078-0432.CCR-11-0411 10.1056/NEJMoa1111097 10.1038/nm0603-669 10.1007/s10549-011-1740-7 10.1161/HYPERTENSIONAHA.110.168120 10.1200/JCO.2010.28.0982 10.1200/JCO.2009.25.4482 10.1158/0008-5472.CAN-04-1443 10.1016/S0735-1097(01)01746-6 10.1023/A:1008217429971 10.1038/bjc.2013.69 10.1186/bcr2899 10.1158/0008-5472.CAN-05-4290 10.1056/NEJMoa1111065 10.1001/jama.289.13.1675 10.1158/1078-0432.CCR-10-1791 10.1200/JCO.2011.36.7771 10.1159/000068620 10.1056/NEJMoa072113 10.1038/sj.bjc.6603515 10.1158/1078-0432.CCR-07-1154 10.1200/JCO.2012.44.7912 10.1161/01.RES.0000089257.94002.96 10.1016/j.cell.2011.02.013 10.1200/JCO.2011.35.3524 10.1200/JCO.2008.16.1612 10.1038/nrc1971 10.1093/jnci/djr128 10.1200/jco.2010.28.15_suppl.1005 10.1158/0008-5472.SABCS-09-42 10.1200/jco.2011.29.15_suppl.1010 10.1158/0008-5472.SABCS12-S6-5 10.1053/sonc.2002.37263 10.1200/jco.2009.27.15_suppl.3527 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media New York 2013 2014 INIST-CNRS COPYRIGHT 2013 Springer |
| Copyright_xml | – notice: Springer Science+Business Media New York 2013 – notice: 2014 INIST-CNRS – notice: COPYRIGHT 2013 Springer |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9- K9. M0R M0S M1P M2O MBDVC PQEST PQQKQ PQUKI Q9U 7X8 |
| DOI | 10.1007/s10549-013-2632-9 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts Consumer Health Database ProQuest Health & Medical Complete (Alumni) Family Health Database (Proquest) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Research Library Research Library (Corporate) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1573-7217 |
| EndPage | 339 |
| ExternalDocumentID | 3035993251 A344603205 10_1007_s10549_013_2632_9 23868188 27632562 |
| Genre | Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | --- -53 -5E -5G -BR -EM -XW -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23N 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIHN ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEAQA AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKNYI BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GUQSH GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICW IHE IHR IHW IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAK LLZTM M0R M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z7W Z7X Z81 Z82 Z83 Z87 Z8O Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM ABFLS ADTIX BBAFP H13 IPNFZ IQODW KSO N95 PQEST PQUKI AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO 7XB 8FK H94 K9. MBDVC Q9U 7X8 |
| ID | FETCH-LOGICAL-c500t-9d8f128d1e62db799bf7b227ba9179afa5f5a5767cc988e4b8c62c59867f7af53 |
| IEDL.DBID | U2A |
| ISSN | 0167-6806 |
| IngestDate | Fri Oct 25 04:07:42 EDT 2024 Thu Oct 10 22:12:42 EDT 2024 Thu Feb 22 23:51:14 EST 2024 Fri Feb 02 04:15:58 EST 2024 Tue Aug 20 22:13:18 EDT 2024 Thu Sep 12 17:28:36 EDT 2024 Tue Oct 15 23:47:02 EDT 2024 Fri Nov 25 01:07:30 EST 2022 Sat Dec 16 12:02:07 EST 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Metastatic breast cancer VEGFR inhibitor Tivozanib Paclitaxel Antineoplastic agent Breast disease Dose escalation Administration schedule Breast cancer Malignant tumor Metastasis Vascular endothelium growth factor receptor Mammary gland diseases Increasing dose Hydrochlorides Taxane derivatives Ureas Advanced stage Inhibitor Antimitotic Cancer |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c500t-9d8f128d1e62db799bf7b227ba9179afa5f5a5767cc988e4b8c62c59867f7af53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
| PMID | 23868188 |
| PQID | 1417402207 |
| PQPubID | 36266 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1418143558 proquest_journals_1417402207 gale_infotracmisc_A344603205 gale_infotracacademiconefile_A344603205 gale_healthsolutions_A344603205 crossref_primary_10_1007_s10549_013_2632_9 pubmed_primary_23868188 pascalfrancis_primary_27632562 springer_journals_10_1007_s10549_013_2632_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-07-01 |
| PublicationDateYYYYMMDD | 2013-07-01 |
| PublicationDate_xml | – month: 07 year: 2013 text: 2013-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Boston |
| PublicationPlace_xml | – name: Boston – name: Dordrecht – name: Netherlands |
| PublicationTitle | Breast cancer research and treatment |
| PublicationTitleAbbrev | Breast Cancer Res Treat |
| PublicationTitleAlternate | Breast Cancer Res Treat |
| PublicationYear | 2013 |
| Publisher | Springer US Springer Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V |
| References | Miles, Chan, Romieu (CR12) 2008; 26 Eskens, de Jonge, Bhargava (CR5) 2011; 17 Goodwin, Seymour, Ding (CR33) 2009; 27 Nosov, Esteves, Lipatov (CR6) 2012; 30 O’Connor, Jackson, Parker (CR34) 2007; 96 Brufsky, Valero, Tiangco (CR22) 2011; 29 Motzer, Nosov, Eisen (CR7) 2012; 30 Brufsky, Bonarenko, Smirnov (CR13) 2009; 69 Bear, Tang, Rastogi (CR24) 2012; 366 Gatza, Kung, Blackwell (CR35) 2011; 13 Nalwoga, Arnes, Stefansson (CR21) 2011; 130 Miller, Wang, Gralow (CR8) 2007; 357 Gianni, Romieu, Lichinitser (CR28) 2013; 31 Mross, Hauns, Haring (CR17) 1998; 9 Bertolini, Shaked, Mancuso (CR30) 2006; 6 Mayer, Dallabrida, Rupnick (CR38) 2011; 58 Ferrara, Gerber, LeCouter (CR3) 2003; 29 Mross, Haring, Hollander (CR18) 2002; 25 Robert, Dieras, Glaspy (CR11) 2011; 29 von Minckwitz, Eidtmann, Rezai (CR23) 2012; 366 Jin, Ueba, Tanimoto (CR37) 2003; 93 Jubb, Miller, Rugo (CR36) 2011; 17 Miles, de Haas, Dirix (CR27) 2013; 108 O’Shaughnessy, Miles, Gray (CR10) 2010; 28 Shishehbor, Aviles, Brennan (CR15) 2003; 289 Foulkes, Brunet, Stefansson (CR20) 2004; 64 Cameron, Brown, Dent (CR25) 2012; 272 Corretti, Anderson, Benjamin (CR16) 2002; 239 Dowlati, Gray, Sandler (CR26) 2008; 14 Schneider, Wang, Radovich (CR29) 2008; 26 Rini, Cohen, Lu (CR32) 2011; 103 Baselga, Segalla, Roche (CR14) 2012; 30 Hanahan, Weinberg (CR1) 2011; 144 Folkman (CR2) 2002; 29 Nakamura, Taguchi, Miura (CR4) 2006; 66 Rugo, Barry, Moreno-Aspitia (CR9) 2012; 30 Wilhelm, Carter, Tang (CR19) 2004; 64 Dahlberg, Sandler, Brahmer (CR31) 2010; 28 MC Corretti (2632_CR16) 2002; 239 K Mross (2632_CR17) 1998; 9 K Miller (2632_CR8) 2007; 357 ML Gatza (2632_CR35) 2011; 13 JP O’Connor (2632_CR34) 2007; 96 H Nalwoga (2632_CR21) 2011; 130 HD Bear (2632_CR24) 2012; 366 R Goodwin (2632_CR33) 2009; 27 K Mross (2632_CR18) 2002; 25 G Minckwitz von (2632_CR23) 2012; 366 DA Nosov (2632_CR6) 2012; 30 K Nakamura (2632_CR4) 2006; 66 J O’Shaughnessy (2632_CR10) 2010; 28 D Hanahan (2632_CR1) 2011; 144 F Bertolini (2632_CR30) 2006; 6 BI Rini (2632_CR32) 2011; 103 RJ Motzer (2632_CR7) 2012; 30 D Miles (2632_CR12) 2008; 26 SM Wilhelm (2632_CR19) 2004; 64 SE Dahlberg (2632_CR31) 2010; 28 N Ferrara (2632_CR3) 2003; 29 A Brufsky (2632_CR13) 2009; 69 J Folkman (2632_CR2) 2002; 29 J Baselga (2632_CR14) 2012; 30 NJ Robert (2632_CR11) 2011; 29 EL Mayer (2632_CR38) 2011; 58 FA Eskens (2632_CR5) 2011; 17 L Gianni (2632_CR28) 2013; 31 AM Jubb (2632_CR36) 2011; 17 D Cameron (2632_CR25) 2012; 272 H Rugo (2632_CR9) 2012; 30 BP Schneider (2632_CR29) 2008; 26 DW Miles (2632_CR27) 2013; 108 ZG Jin (2632_CR37) 2003; 93 MH Shishehbor (2632_CR15) 2003; 289 A Brufsky (2632_CR22) 2011; 29 WD Foulkes (2632_CR20) 2004; 64 A Dowlati (2632_CR26) 2008; 14 |
| References_xml | – volume: 64 start-page: 830 year: 2004 end-page: 835 ident: CR20 article-title: The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-2970 contributor: fullname: Stefansson – volume: 30 start-page: 277s year: 2012 ident: CR7 article-title: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.4133 contributor: fullname: Eisen – volume: 17 start-page: 7156 year: 2011 end-page: 7163 ident: CR5 article-title: Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0411 contributor: fullname: Bhargava – volume: 366 start-page: 310 year: 2012 end-page: 320 ident: CR24 article-title: Bevacizumab added to neoadjuvant chemotherapy for breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1111097 contributor: fullname: Rastogi – volume: 29 start-page: 669 year: 2003 end-page: 676 ident: CR3 article-title: The biology of VEGF and its receptors publication-title: Nat Med doi: 10.1038/nm0603-669 contributor: fullname: LeCouter – volume: 130 start-page: 1063 year: 2011 end-page: 1071 ident: CR21 article-title: Vascular proliferation is increased in basal-like breast cancer publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1740-7 contributor: fullname: Stefansson – volume: 58 start-page: 85 year: 2011 end-page: 92 ident: CR38 article-title: Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.110.168120 contributor: fullname: Rupnick – volume: 29 start-page: 1252 year: 2011 end-page: 1260 ident: CR11 article-title: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2010.28.0982 contributor: fullname: Glaspy – volume: 69 start-page: abstract 42 issue: 24 suppl year: 2009 ident: CR13 article-title: RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer publication-title: Cancer Res contributor: fullname: Smirnov – volume: 28 start-page: 949 year: 2010 end-page: 954 ident: CR31 article-title: Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.4482 contributor: fullname: Brahmer – volume: 64 start-page: 7099 year: 2004 end-page: 7109 ident: CR19 article-title: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-1443 contributor: fullname: Tang – volume: 239 start-page: 257 year: 2002 end-page: 265 ident: CR16 article-title: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(01)01746-6 contributor: fullname: Benjamin – volume: 9 start-page: 569 year: 1998 end-page: 572 ident: CR17 article-title: Clinical phase I study with one-hour paclitaxel infusion publication-title: Ann Oncol doi: 10.1023/A:1008217429971 contributor: fullname: Haring – volume: 108 start-page: 1052 year: 2013 end-page: 1060 ident: CR27 article-title: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer publication-title: Br J Cancer doi: 10.1038/bjc.2013.69 contributor: fullname: Dirix – volume: 13 start-page: abstract R62 year: 2011 ident: CR35 article-title: Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes publication-title: Breast Cancer Res doi: 10.1186/bcr2899 contributor: fullname: Blackwell – volume: 66 start-page: 9134 year: 2006 end-page: 9142 ident: CR4 article-title: KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-4290 contributor: fullname: Miura – volume: 29 start-page: abstract 1010 issue: 82 suppl year: 2011 ident: CR22 article-title: Bevacizumab (BEV) plus second-line taxane (TAX) or other chemotherapy (CT) for triple-negative breast cancer (TNBC): subgroup analysis of RIBBON-2 publication-title: J Clin Oncol contributor: fullname: Tiangco – volume: 28 start-page: abstract 1005 issue: 15 suppl year: 2010 ident: CR10 article-title: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) publication-title: J Clin Oncol contributor: fullname: Gray – volume: 366 start-page: 299 year: 2012 end-page: 309 ident: CR23 article-title: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1111065 contributor: fullname: Rezai – volume: 289 start-page: 1675 year: 2003 end-page: 1680 ident: CR15 article-title: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy publication-title: JAMA doi: 10.1001/jama.289.13.1675 contributor: fullname: Brennan – volume: 17 start-page: 372 year: 2011 end-page: 381 ident: CR36 article-title: Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-1791 contributor: fullname: Rugo – volume: 30 start-page: 1484 year: 2012 end-page: 1491 ident: CR14 article-title: Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.7771 contributor: fullname: Roche – volume: 25 start-page: 503 year: 2002 end-page: 508 ident: CR18 article-title: Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial publication-title: Onkologie doi: 10.1159/000068620 contributor: fullname: Hollander – volume: 29 start-page: 15 year: 2002 end-page: 18 ident: CR2 article-title: Role of angiogenesis in tumor growth and metastasis publication-title: Semin Oncol contributor: fullname: Folkman – volume: 357 start-page: 2666 year: 2007 end-page: 2676 ident: CR8 article-title: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa072113 contributor: fullname: Gralow – volume: 30 start-page: abstract CRA1002 issue: 18 suppl year: 2012 ident: CR9 article-title: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) publication-title: J Clin Oncol contributor: fullname: Moreno-Aspitia – volume: 27 start-page: abstract 3527 issue: 152 suppl year: 2009 ident: CR33 article-title: Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: a randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer publication-title: J Clin Oncol contributor: fullname: Ding – volume: 96 start-page: 189 year: 2007 end-page: 195 ident: CR34 article-title: DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603515 contributor: fullname: Parker – volume: 14 start-page: 1407 year: 2008 end-page: 1412 ident: CR26 article-title: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern Cooperative Oncology Group Study publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1154 contributor: fullname: Sandler – volume: 31 start-page: 1719 year: 2013 end-page: 1725 ident: CR28 article-title: AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.7912 contributor: fullname: Lichinitser – volume: 93 start-page: 354 year: 2003 end-page: 363 ident: CR37 article-title: Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase publication-title: Circ Res doi: 10.1161/01.RES.0000089257.94002.96 contributor: fullname: Tanimoto – volume: 144 start-page: 646 year: 2011 end-page: 674 ident: CR1 article-title: Hallmarks of cancer: the next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 contributor: fullname: Weinberg – volume: 30 start-page: 1678 year: 2012 end-page: 1685 ident: CR6 article-title: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.3524 contributor: fullname: Lipatov – volume: 26 start-page: 4672 year: 2008 end-page: 4678 ident: CR29 article-title: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.1612 contributor: fullname: Radovich – volume: 6 start-page: 835 year: 2006 end-page: 845 ident: CR30 article-title: The multifaceted circulating endothelial cell in cancer: towards marker and target identification publication-title: Nat Rev Cancer doi: 10.1038/nrc1971 contributor: fullname: Mancuso – volume: 26 start-page: abstract LBA1011 issue: 20 suppl year: 2008 ident: CR12 article-title: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO publication-title: J Clin Oncol contributor: fullname: Romieu – volume: 272 start-page: abstract S6-5 year: 2012 ident: CR25 article-title: Primary results of BEATRICE, a randomized Phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer publication-title: Cancer Res contributor: fullname: Dent – volume: 103 start-page: 763 year: 2011 end-page: 773 ident: CR32 article-title: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djr128 contributor: fullname: Lu – volume: 13 start-page: abstract R62 year: 2011 ident: 2632_CR35 publication-title: Breast Cancer Res doi: 10.1186/bcr2899 contributor: fullname: ML Gatza – volume: 58 start-page: 85 year: 2011 ident: 2632_CR38 publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.110.168120 contributor: fullname: EL Mayer – volume: 103 start-page: 763 year: 2011 ident: 2632_CR32 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djr128 contributor: fullname: BI Rini – volume: 28 start-page: abstract 1005 issue: 15 suppl year: 2010 ident: 2632_CR10 publication-title: J Clin Oncol doi: 10.1200/jco.2010.28.15_suppl.1005 contributor: fullname: J O’Shaughnessy – volume: 108 start-page: 1052 year: 2013 ident: 2632_CR27 publication-title: Br J Cancer doi: 10.1038/bjc.2013.69 contributor: fullname: DW Miles – volume: 29 start-page: 669 year: 2003 ident: 2632_CR3 publication-title: Nat Med doi: 10.1038/nm0603-669 contributor: fullname: N Ferrara – volume: 25 start-page: 503 year: 2002 ident: 2632_CR18 publication-title: Onkologie doi: 10.1159/000068620 contributor: fullname: K Mross – volume: 289 start-page: 1675 year: 2003 ident: 2632_CR15 publication-title: JAMA doi: 10.1001/jama.289.13.1675 contributor: fullname: MH Shishehbor – volume: 26 start-page: 4672 year: 2008 ident: 2632_CR29 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.1612 contributor: fullname: BP Schneider – volume: 30 start-page: abstract CRA100 issue: 18 suppl year: 2012 ident: 2632_CR9 publication-title: J Clin Oncol contributor: fullname: H Rugo – volume: 28 start-page: 949 year: 2010 ident: 2632_CR31 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.4482 contributor: fullname: SE Dahlberg – volume: 30 start-page: 1678 year: 2012 ident: 2632_CR6 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.3524 contributor: fullname: DA Nosov – volume: 30 start-page: 277s year: 2012 ident: 2632_CR7 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.4133 contributor: fullname: RJ Motzer – volume: 93 start-page: 354 year: 2003 ident: 2632_CR37 publication-title: Circ Res doi: 10.1161/01.RES.0000089257.94002.96 contributor: fullname: ZG Jin – volume: 17 start-page: 7156 year: 2011 ident: 2632_CR5 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0411 contributor: fullname: FA Eskens – volume: 17 start-page: 372 year: 2011 ident: 2632_CR36 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-1791 contributor: fullname: AM Jubb – volume: 366 start-page: 299 year: 2012 ident: 2632_CR23 publication-title: N Engl J Med doi: 10.1056/NEJMoa1111065 contributor: fullname: G Minckwitz von – volume: 30 start-page: 1484 year: 2012 ident: 2632_CR14 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.7771 contributor: fullname: J Baselga – volume: 9 start-page: 569 year: 1998 ident: 2632_CR17 publication-title: Ann Oncol doi: 10.1023/A:1008217429971 contributor: fullname: K Mross – volume: 26 start-page: abstract LBA101 issue: 20 suppl year: 2008 ident: 2632_CR12 publication-title: J Clin Oncol contributor: fullname: D Miles – volume: 69 start-page: abstract 42 issue: 24 suppl year: 2009 ident: 2632_CR13 publication-title: Cancer Res doi: 10.1158/0008-5472.SABCS-09-42 contributor: fullname: A Brufsky – volume: 29 start-page: abstract 1010 issue: 82 suppl year: 2011 ident: 2632_CR22 publication-title: J Clin Oncol doi: 10.1200/jco.2011.29.15_suppl.1010 contributor: fullname: A Brufsky – volume: 6 start-page: 835 year: 2006 ident: 2632_CR30 publication-title: Nat Rev Cancer doi: 10.1038/nrc1971 contributor: fullname: F Bertolini – volume: 130 start-page: 1063 year: 2011 ident: 2632_CR21 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1740-7 contributor: fullname: H Nalwoga – volume: 239 start-page: 257 year: 2002 ident: 2632_CR16 publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(01)01746-6 contributor: fullname: MC Corretti – volume: 64 start-page: 7099 year: 2004 ident: 2632_CR19 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-1443 contributor: fullname: SM Wilhelm – volume: 272 start-page: abstract S6-5 year: 2012 ident: 2632_CR25 publication-title: Cancer Res doi: 10.1158/0008-5472.SABCS12-S6-5 contributor: fullname: D Cameron – volume: 96 start-page: 189 year: 2007 ident: 2632_CR34 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603515 contributor: fullname: JP O’Connor – volume: 64 start-page: 830 year: 2004 ident: 2632_CR20 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-2970 contributor: fullname: WD Foulkes – volume: 29 start-page: 15 year: 2002 ident: 2632_CR2 publication-title: Semin Oncol doi: 10.1053/sonc.2002.37263 contributor: fullname: J Folkman – volume: 29 start-page: 1252 year: 2011 ident: 2632_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.28.0982 contributor: fullname: NJ Robert – volume: 366 start-page: 310 year: 2012 ident: 2632_CR24 publication-title: N Engl J Med doi: 10.1056/NEJMoa1111097 contributor: fullname: HD Bear – volume: 14 start-page: 1407 year: 2008 ident: 2632_CR26 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1154 contributor: fullname: A Dowlati – volume: 27 start-page: abstract 3527 issue: 152 suppl year: 2009 ident: 2632_CR33 publication-title: J Clin Oncol doi: 10.1200/jco.2009.27.15_suppl.3527 contributor: fullname: R Goodwin – volume: 357 start-page: 2666 year: 2007 ident: 2632_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa072113 contributor: fullname: K Miller – volume: 144 start-page: 646 year: 2011 ident: 2632_CR1 publication-title: Cell doi: 10.1016/j.cell.2011.02.013 contributor: fullname: D Hanahan – volume: 66 start-page: 9134 year: 2006 ident: 2632_CR4 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-4290 contributor: fullname: K Nakamura – volume: 31 start-page: 1719 year: 2013 ident: 2632_CR28 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.7912 contributor: fullname: L Gianni |
| SSID | ssj0009709 |
| Score | 2.2338352 |
| Snippet | Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study... |
| SourceID | proquest gale crossref pubmed pascalfrancis springer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 331 |
| SubjectTerms | Adult Aged Angiogenesis Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer Cancer research Cancer therapies Care and treatment Clinical Trial Dose-Response Relationship, Drug Drug-Related Side Effects and Adverse Reactions - classification Drug-Related Side Effects and Adverse Reactions - pathology Female Gynecology. Andrology. Obstetrics Humans Inhibitor drugs Kinases Mammary gland diseases Medical sciences Medicine Medicine & Public Health Metastasis Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Metastasis - drug therapy Neoplasm Metastasis - genetics Neoplasm Metastasis - pathology Oncology Oncology, Experimental Paclitaxel - administration & dosage Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Phenylurea Compounds - pharmacokinetics Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Quinolines - administration & dosage Quinolines - adverse effects Quinolines - pharmacokinetics Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors Vascular Endothelial Growth Factor Receptor-1 - metabolism |
| SummonAdditionalLinks | – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ri9QwEA-6ByKI-LZ6nhEEQSnupk2TfpJVdj2FO47Dk_tW8mQXtF13e_j45n_uTJruWnx8TpqGzCMzmZnfEPLUcKuV8zJV4Fukuc9BpLA4x-VKKVt4rTkWJx8dF4dn-ftzfh4f3DYxrbLXiUFR28bgG_nLSQ62M5aFilerLyl2jcLoamyhcZnsMfAU2IjsvZ4dn5zuYHdFl-SB6N6FHBd9XLMrngPfKMXuBohZnpaDmynq52srtYGz8l2Ti79ZoX9EUMPFNL9BrkeLkk47FrhJLrn6FrlyFGPmt8nPKT1ZwF1F31HbbFzq8FeBHjRgy9LGU7AC6cfZ2_kpXdaLpQYpX1PQg80PVS81XXy32FgLc_Wso_hyS78GIH4KDjeCfH9zn-BD-tm1CguUloZqzHVvqUGeWt8hZ_PZhzeHaWy8kBo-HrdpaaWHe8tOXMGsFmWpvdCMCa3AuSuVV9xzBY6KMKaU0uVamoIZRHoXXijPs7tkVDe1u08oM6ED4MT7LETwJAcXRludFcIZq31CnveHXq06fI1qh6SMFKqAQhVSqCoT8hjJUnUlolvZrKYZOLXYCZ4n5FmYgdLZrpVRscgANoM4V4OZ-4OZIFVmMHwwIP12cwwUMpiJDL7veaGKYr-pdkyakCfbYVwaU9lq11yEORKNVC4Tcq_jod3imSzAgoKRFz1T_bb4v47lwf-38pBcZaGHB-YY75NRu75wj8CSavVBFJdf8yQZ6Q priority: 102 providerName: ProQuest |
| Title | A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer |
| URI | https://link.springer.com/article/10.1007/s10549-013-2632-9 https://www.ncbi.nlm.nih.gov/pubmed/23868188 https://www.proquest.com/docview/1417402207 https://search.proquest.com/docview/1418143558 |
| Volume | 140 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF_6ASKI-G20nisIgpJyl2Szm8dY7lqVllI8OZ_CfnKHbVLuUvx48z93ZpPcNVgffEkedrJZdnZ2Z3ZmfkPIa82MktaJUIJtESYuAZHC5BybSClN6pRimJx8fJIeTZOPMzbbItH66qL8tt95JP1GfS3XDUyZEIsRIMR4mG2TXdAdEgzjmkb5BmiXN2EdiOedimHaeTJv6qJ3FrU78p1LuYLZcU1Zi5v0zr98pv4omtwjd1sdkuYN0--TLVs-ILeOWy_5Q_I7p6dzOJ3oB2qqlQ0t_spzgHo0WVo5Cnof_TI-nJzRRTlfKJDrJYWdr_oly4Wi858GS2lhdJ6xFO9q6XcPvU_BxEZY7x_2HD6kF7aWmJK00FRhdHtNNa6i5SMynYw_HxyFbamFULPhsA4zIxycVGZk08gonmXKcRVFXEkw5zLpJHNMgmnCtc6EsIkSOo00Yrtzx6Vj8WOyU1alfUpopH3Nv5FzsffZCQZGizIqTrnVRrmAvO0mvbhsEDWKDXYycqgADhXIoSILyEtkS9Ekha6lschjMGOx9jsLyBtPgfJYL6WWbVoBDAaRrXqUez1KkCPdax70WL8eXARbMCiGEXzfrYWiFfQVWE5g0mG2Mg_Iq3Uzdo3Ba6WtrjyNQLWUiYA8adbQpvNYpKAzQcu7blFd6_xf0_Lsv6ifk9uRL-KBQcZ7ZKdeXtkXoErVakC2-YzDUxyMBmQ3P_z6aQzv9-OT07OBl6s_BekZpg |
| link.rule.ids | 315,783,787,12070,12237,21402,27938,27939,31733,31734,33280,33281,33758,33759,41095,41537,42164,42606,43324,43593,43819,52125,52248,74081,74350,74638 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ri9QwEA96ggoivq963kUQBKXcbts06SdZ5NY9vT1E7mS_hTzZBa9dd3v4-OZ_7kza7lp8fE6ahswjM5mZ3xDy3DCrlfMiVuBbxJnPQKSwOMdlSimbe60ZFidPT_PJefZuxmbtg9u6TavsdGJQ1LYy-EZ-OMzAdsayUP56-SXGrlEYXW1baFwl1xCHC7Hz-YxvQXd5k-KB2N65GORdVLMpnQPPKMbeBohYHhe9e6nVzreWag0n5ZsWF3-zQf-In4ZraXyH3G7tSTpqGOAuueLKe-T6tI2Y3yc_R_TDHG4qekxttXaxw18FatCALEsrT8EGpJ-O3o4_0kU5X2iQ8RUFLVj9UOVC0_l3i221MFPPOorvtvRrgOGn4G4jxPc39xk-pBeuVlietDBUY6Z7TQ1y1OoBOR8fnb2ZxG3bhdiwwaCOCys83Fp26PLEal4U2nOdJFwrcO0K5RXzTIGbwo0phHCZFiZPDOK8c8-VZ-lDslNWpdslNDGh_9_Q-zTE7wQDB0ZbnebcGat9RF52hy6XDbqG3OIoI4UkUEgihWQRkQMki2wKRDeSKUcpuLTYB55F5EWYgbJZr5RRbYkBbAZRrnoz93ozQaZMb3i_R_rN5hJQx2AkJvB9xwuyFfq13LJoRJ5thnFpTGQrXXUZ5gg0UZmIyKOGh7aLpyIH-wlGXnVM9dvi_zqWx__fygG5MTmbnsiT49P3T8jNJHTzwGzjPbJTry7dU7Cpar0fBOcXmYobdA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RAFB60hSKIWC81trYjCIISuptkksmTLLVrq7YUsdK3Ya7sQpusuylW3_znnjOZ7Bq8PM9kMsy5zDlzLh8hLzQzSlrHYwm-RZy5DEQKi3NsJqU0uVOKYXHyyWl-dJ69v2AXIf9pEdIqO53oFbWpNb6R7w8zsJ2xLLTYdyEt4uzt-M3sa4wIUhhpDXAat8k63IoMYRz4wSrdoyzadA_s853zQd5FONsyOvCSYsQ5wO7lcdm7o4KmvjuTCzg118Jd_M0e_SOW6q-o8X1yL9iWdNQywya5ZasHZOMkRM8fkp8jejaBW4seU1MvbGzxV54y1HeZpbWjYA_SL4fvxp_otJpMFcj7nIJGrH_Iaqro5LtBiC3M2jOW4hsu_eZb8lNwvbHd9429hA_plW0klipNNVWY9d5Qjdw1f0TOx4efD47iAMEQazYYNHFpuIMbzAxtnhhVlKVyhUqSQklw80rpJHNMgstSaF1ybjPFdZ5o7PleuEI6lj4ma1Vd2SeEJtpjAQ6dS30sjzNwZpRRaV5YbZSLyKvu0MWs7bQhVj2VkUICKCSQQqKMyB6SRbTFokspFaMU3FvEhGcReelnoJw2c6llKDeAzWDHq97Mnd5MkC_dG97tkX65uQRUMxiMCXzf8YIICmAhVuwakefLYVwak9oqW1_7ORzNVcYjstXy0GrxlOdgS8HI646pflv8X8fy9P9b2SMbIDPi4_Hph21yJ_HAHph4vEPWmvm1fQbmVaN2vdz8At5lH3Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Phase+I+dose-escalation+study+of+the+VEGFR+inhibitor+tivozanib+hydrochloride+with+weekly+paclitaxel+in+metastatic+breast+cancer&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=Mayer%2C+Erica+L&rft.au=Scheulen%2C+M+E&rft.au=Beckman%2C+J&rft.au=Richly%2C+H&rft.date=2013-07-01&rft.eissn=1573-7217&rft.volume=140&rft.issue=2&rft.spage=331&rft.epage=339&rft_id=info:doi/10.1007%2Fs10549-013-2632-9&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon |